RECRUITING

4D-710 in Adult Patients with Cystic Fibrosis

Talk to us

Conditions

Cystic Fibrosis LungCFCystic FibrosisGene Therapy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.

Official Title

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults with Cystic Fibrosis

Quick Facts

Study Start:2022-03-29
Study Completion:2030-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05248230

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

4DMT Patient Advocacy
CONTACT
(888) 748-8881
clinicaltrials@4DMT.com

Principal Investigator

Alan H. Cohen, MD
STUDY_DIRECTOR
4D Molecular Therapeutics

Study Locations (Sites)

University of Alabama Child Health Research Unit
Birmingham, Alabama, 35233
United States
University of California San Francisco
San Francisco, California, 94143
United States
National Jewish Health
Denver, Colorado, 80206
United States
University of Florida
Gainesville, Florida, 32610
United States
Northwestern Memorial Hospital
Chicago, Illinois, 60611
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Boston Children's Hospital
Boston, Massachusetts, 02115
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
United States
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44146
United States
Nationwide Children's Hospital
Columbus, Ohio, 43205
United States
Penn State Health
Hershey, Pennsylvania, 17033
United States
The Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390
United States
Virginia Commonwealth University Health System
Richmond, Virginia, 23298
United States
University of Washington Medical Center
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: 4D Molecular Therapeutics

  • Alan H. Cohen, MD, STUDY_DIRECTOR, 4D Molecular Therapeutics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-03-29
Study Completion Date2030-01

Study Record Updates

Study Start Date2022-03-29
Study Completion Date2030-01

Terms related to this study

Keywords Provided by Researchers

  • CF
  • Cystic Fibrosis
  • Gene Therapy

Additional Relevant MeSH Terms

  • Cystic Fibrosis Lung